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Among important components of American ginseng, protopanaxadiol (PPD) showed more active anti-
cancer potential than other triterpenoid saponins. In this study, we determined the in vivo effects of PPD
in a mouse cancer model ﬁrst. Then, using human colorectal cancer cell lines, we observed signiﬁcant
cancer cell growth inhibition by promoting G1 cell cycle redistribution and apoptosis. Subsequently, we
characterized the downstream genes targeted by PPD in HCT-116 cancer cells. Using Affymetrix high
density GeneChips, we obtained the gene expression proﬁle of the cells. Microarray data indicated that
the expression levels of 76 genes were changed over two-fold after PPD, of which 52 were upregulated
while the remaining 24 were downregulated. Ingenuity pathway analysis of top functions affected was
carried out. Data suggested that by regulating the interactions between p53 and DR4/DR5, the tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway played a key role in the action of PPD,
a promising colon cancer inhibitory compound.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is one of the most common cancers and
a leading cause of cancer death in both men and women. Although
promising progress has been made in the diagnosis and treatment
of CRC over the last decade, this cancer remains a major public
health problem (1e3). There is an urgent demand to better un-
derstand the molecular mechanisms underlying the different
phenotypes of CRC. This understanding may provide information
supporting drug discovery and prevention strategies (1). The
development of human genome technologies, such as DNA micro-
arrays, has allowed us to simultaneously examine thousands of
genes, leading to a better understanding of carcinogenesis (4).dicine Research, The Pritzker
Maryland Avenue, MC 4028,
an).
acological Society.
. Production and hosting by ElseStudies related to compound treatment outcomes by differences in
gene expression proﬁling facilitate the search for more curative
interventions (5).
Increasing evidence shows that patients with cancer often resort
to complementary and alternative medical supplements to treat
cancer, cancer-related symptoms, or to reduce the adverse effects of
chemotherapy (6). Botanicals can contain effective anticancer com-
pounds that can be used alone or as adjuncts to existing chemo-
therapy, thereby improving efﬁcacy and reducing drug-induced
adverse events (7,8). In current cancer treatment, approximately 80%
of novel drugs have originated from natural products (9).
American ginseng (Panax quinquefolius L.) is a commonly used
herbal medicine in the United States. Protopanaxadiol (PPD, Fig. 1),
an aglycon of ginseng saponins from the ginseng, has shown anti-
cancer potential in our previous studies (10). However, the previous
study emphasized in vitro bioactivity screening using PPD and its
derivatives, the in vivo antitumor effects were not evaluated. In
addition, PPD’s anti-CRC mechanisms have largely not been
explored.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Chemical structure of protopanaxadiol (PPD).
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sent study, we ﬁrst used an athymic nude mouse xenograft tumor
model to observe the compound’s in vivo activity. Next, a panel of
human colorectal cancer cell lines (i.e., SW-480, HT-29, and HCT-
116), which differ in the expression of the tumor suppressor gene,
p53, were used to compare the anti-proliferation activities. Then,
HCT-116 cells, which showed themost signiﬁcant growth inhibition
by PPD, were selected to explore the compound’s effect on mRNA.
Our data showed that PPD was involved in the upregulation of
several tumor suppressor genes, suggesting that DR4/DR5 (a tumor
necrosis factor-related apoptosis-inducing ligand, or TRAIL) was
associated with the anticancer effect of PPD.
2. Materials and methods
2.1. Protopanaxadiol (PPD) preparation
Total ginsenosides (2.0 g), n-butanol (250 mL), and sodium hy-
droxide (10 g) were added to a 500 ml round bottom ﬂask. The
mixture was heated to 130 C stirring with argon for 2 days and
allowed to cool at room temperature. Then, the reaction mixture
was washed with water (2  100 mL), 1% HCl (2  100 ml), 5%
NaHCO3, and brine. The organic phase was dried over magnesium
sulfate. The removal of the solvent under reduced pressure resulted
in a sticky oil, which was puriﬁed by a silica gel column to release
PPD. PPD was dissolved in DMSO to make stock solution (varied
concentrations 5e40 mM) and kept at 80 C as aliquots before
use.
2.2. HCT-116-Luc cell line, xenograft tumor model and
bioluminescence imaging
The HCT-116-Luc cells that stably express ﬁreﬂy luciferase were
used as described previously (11,12). The ﬁreﬂy luciferase activity
was tested using Promega's Luciferase Assay kit (Promega, Madi-
son, WI). Female athymic nude mice (Harlan Sprague-Dawley,
Indianapolis, IN), 4 weeks old and 10 mice per group, were used.
The use and care of animals was performed following the guide-
lines approved by the Institutional Animal Care and Use Committee
(ACUP number: 70917, approved on April 4, 2013).
Subconﬂuent HCT-116-Luc cells were harvested and resus-
pended in phosphate buffered saline (PBS) to a density of
2.0  107 cells/mL. Before injection, cell viability was analyzed by
0.4% trypan blue (viable cells > 90%). For subcutaneous injection,
approximately 1.0  106 HCT116-Luc cells in 50 mL PBS were
injected into both ﬂanks of each animal. From the same day of
inoculation, PPD (25 or 50 mg/kg body weight) was administered
intraperitoneally (IP) every other day until the experiment ended.
Optical imaging procedure and analysis was carried out as
described previously (13).
Animals were subjected to Xenogen IVIS 200 imaging system
(Caliper Life Sciences, Hopkinton, MA) for imaging at indicated timepoints after HCT-116-Luc cell inoculation. D-Luciferin sodium salt
(Gold Biotechnology, St. Louis, MO) at 100 mg/kg body weight in
0.1 mL sterile PBS was administered IP as a substrate before each
imaging. Pseudo images were acquired by superimposing the
emitted light over the grayscale photographs of the animal.
Quantitative image analysis was performed with Xenogen's Living
Image V4.0.1 software.
2.3. Cell culture and cell proliferation inhibition analysis
SW-480, HT-29, HCT-116 human colorectal cancer cells, and IEC-
6 rat small intestine epithelial cells were purchased from American
Type Culture Collection (ATCC, Manassas, VA) and grown in the L-
15 or McCoy's 5A medium supplemented with 10% FBS and 50 IU
penicillin/streptomycin in a humidiﬁed atmosphere of 5% CO2
(100% air for SW-480 cells) at 37 C. For the proliferation assay, each
type of cell was seeded in 96-well plates (5  103 cells/well) to
adhere overnight. Various concentrations of PPD (5, 10, 20, 30, and
40 mM) thenwere administrated to the wells. Controls were treated
with culture medium containing 0.1% DMSO. After 24, 48, and 72 h,
cell survival and growth were measured by the Cell Titer 96
Aqueous MTS Reagent (Promega, Madison, WI) according to the
manufacturer’s protocol. All experiments were performed in trip-
licate and repeated three times, independently. The light absor-
bance was measured by using an automatic microplate reader
(Epoch, Bio-Tek Instruments, Winooski, VT) at 490 nm (14). Data
were expressed as a percentage versus control (vehicle set at 100%).
2.4. Apoptosis assay
HCT-116 and SW-480 cells were seeded in 24-well plates. After
24 h, the medium was changed and PPD was added at different
concentrations. After treatment for 48 h, all adherent cells were
collected with 0.05% trypsin, including the ﬂoating cells in the
medium, and centrifuged for 5 min at 600 g. Then, the cells were
double stained with Annexin-V-(FITC) and propidium iodide (PI)
(Becton Dickinson, San Diego, CA) according to the manufacturer's
instructions (15). Untreated cells were used as control. The stained
cells were subsequently analyzed by a FACS Canto ﬂow cytometer
(Becton Dickinson, Mountain View, CA). All experiments were
performed independently three times, and run in triplicate. At least
10,000 cells were counted each time. Datawere analyzed by FlowJo
software 9.0.
2.5. Cell cycle assay
For cell cycle assay, 1  105 cells were seeded in 12-well plates.
On the second day, PPD or vehicle was added. 48 h later, all
adherent cells were collected by trypsin, ﬁxed with 80% ethanol
and stored for 2 h at 20 C. After treatment with 0.25% Triton X-
100 for 5 min, the cells were resuspended in 200 mL of PI/RNase
staining buffer (Becton Dickinson, San Diego, CA), incubated in the
dark for 20 min at room temperature, and counted with a FACS
Canto ﬂow cytometer. At least 10,000 cells were counted for each
measurement. Data were analyzed by FlowJo software 9.0.
2.6. HCT-116 cell treatment protocol and total RNA preparation
HCT-116 cells were plated at a density of 1  105 cells/dish in
60 mm tissue culture plates. Cells were allowed to adhere for
24 h before treatment. Thereafter, cells were treated with 20 or
25 mM of PPD for 24 or 48 h. Total RNA was extracted using miR-
Neasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer's
instruction and quantiﬁed by NanoDrop (Thermo, Wilmington, DE)
before hybridization.
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A group of 6 samples obtained from the in vitro assays were
included in the cDNA array assays. Gene arrays were performed by
using Affymetrix GeneChip Human Gene 1.0 ST Array (Dumbarton
Circle, Fremont, CA), which contains 28,853 mouse genes being
represented on the array by approximately 27 probes spread across
the full length of a given gene. This provides a more complete and
more accurate picture of gene expression than 30-based expression
array designs. After hybridization and background correction ac-
cording to the standard protocols, the quantiﬁed signals were then
normalized using Robust Multi-array Average (RMA), which is a
robust algorithm of background-adjustment, quantile normaliza-
tion, and log-transformation (16). Partek Genomics Suite (Partek
Inc., St. Louis, MI) was used for the analysis of the normalized data.
2.8. Q-PCR analysis of core genes
The differential expression level of a subset of genes selected
from highly expressed genes by microarray was conﬁrmed by
quantitative real-time RT-PCR analysis. Isolated RNA was reverse
transcribed and the resulting cDNA was then ampliﬁed using SYBR
green and speciﬁc primers according to the manufacturer’s in-
structions (Applied Biosystems, Carlsbad, CA). All samples were run
in triplicate and the expression of each gene was standardized
using the housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) as a reference. Ampliﬁcation reactions were
performed using a 9700H real-time PCR instrument (Applied Bio-
systems, Carlsbad, CA). The conditions for the reactions were: 95 C,
10 min; 95 C, 15 s; 60 C, 60 s for 40 cycles. The related genes
expression was determined using 2△△ct method.
2.9. Statistical analysis
Data are expressed as mean ± SE. A one-way ANOVA determined
whether the results had statistical signiﬁcance. In some cases, a
Student's t-test was used to compare the two groups. A P-value set atFig. 2. PPD inhibits tumor growth in xenograft mice with colorectal cancer. (A) HCT-116 indu
days. Representative Xenogen imaging results (Control, PPD 25 mg/kg and PPD 50 mg/kg)
imaging. Average tumor sizes at the indicated time points are represented with imaging sig
growth in Athymic nude mice in a dose dependent manner (n ¼ 10). ** P < 0.01, compared0.05 was used to determine signiﬁcant differences. All analyses were
performed using SPSS 14.0 (IBM Corporation, Somers, NY).
3. Results
3.1. PPD signiﬁcantly inhibits the growth of xenograft tumors in
Athymic nude mice
Xenograft tumor model mice implanted with HCT-116 human
colorectal carcinoma cells were administrated with 25 and 50mg/kg
PPD.After30daysof treatment, 25and50mg/kgPPD inhibited tumor
growth approximately by 35% and 50%, respectively (Fig. 2: A and B;
P< 0.01 compared to control, P< 0.05, compared to 25mg/kg group).
With the assistance of veterinary staff in the animal care facility
in our university, no obvious clinical signs of adverse events were
observed during the PPD treatment. These daily observations
included: motor activity (locomotion, catalepsy), respiration (dys-
pnea), skin (edema, erythema), and reﬂexes (light) (17).
3.2. PPD signiﬁcantly inhibits colorectal cancer cell proliferation
Growth inhibitory effects of PPD on SW-480, HT-29, and HCT-
116 cancer cells at various PPD concentrations (5, 10, 20, 30 and
40 mM) were evaluated at 24, 48 or 72 h. The MTS assay results
are shown in Fig. 3A, B and C. The growth of the treated cells
decreased signiﬁcantly in a concentration-dependent manner.
We also observed that, PPD at 20 mM, HCT-116 cells were
signiﬁcantly more sensitive to the treatment than the other two
cells, suggesting that the status of p53 could account for this
difference.
A normal rat small intestine epithelial cell line, IEC-6, was used
to evaluate the effects of PPD. Compared with the control (100%),
the cell viabilities of PPD on IEC-6 cells in 10, 20, 30 and 40 mM for
48 h were 100.8 ± 5.0%, 103.5 ± 4.8%, 101.4 ± 7.3%, and 86.3 ± 6.6%,
respectively. In contrast, cell growth was almost totally inhibited in
all the three colorectal cancer cell lines when treated with PPD at
30 mM (Fig. 3).ced tumor growth was monitored using Xenogen bioluminescence imaging for up to 30
at day 1 and day 30 are shown. (B) Quantitative analysis of Xenogen bioluminescence
nal intensities (in photons/second/cm2/steradian). PPD signiﬁcantly inhibits the tumor
with control; # P < 0.01, compared with 25 mg/kg group).
Fig. 3. PPD inhibits the growth of SW-480, HT-29, and HCT-116 human colorectal cancer cells. Cell survival was determined by MTS assay and calculated as a ratio of the control.
PPD inhibited SW-480 cell (A), HT-29 (B), and HCT-116 cell (C) proliferation in a time- and concentration-dependent manner. (D) HCT-116 cells showed more sensitivity than the
other two cell lines after 20 mM PPD treatment. Data are presented as triplicate wells and three independent experiments. * P < 0.05, ** P < 0.01, compared with control.
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HCT-116 and SW-480 cells were treated with different PPD
concentrations (15, 20, 25, 30, and 35 mM) for 72 h. The apoptotic
cells were determined by ﬂow cytometry using Annexin-V/propi-
dium iodide (PI) double labeling. The ratio of apoptotic cells was
signiﬁcantly increased, dependent on PPD concentration (i.e.,
>20 mM, consistent with the above cell proliferative data),
compared with control (Fig. 4A; P < 0.01).
3.4. PPD induces cell G1 cycle arrest in cancer cells
HCT-116 and SW-480 cells were treated with different concen-
trations (15, 20, 25, 30, and 35 mM) of PPD for 48 h and the cell cycle
was examined by ﬂow cytometry. As shown in Fig. 4B, PPD-induced
G1 cell cycle arrest in a concentration-dependent manner in both
cell lines (both P < 0.01).
3.5. mRNA expression proﬁling and quantitative real-time PCR
(qPCR) analysis after exposure of PPD to HCT-116 cells
HCT-116 cells were selected to perform mRNAs expression
proﬁling analysis on six samples, including three control vehicle
treated cells and different concentrations and time points of PPD-
treated cells. We ﬁrst performed an unsupervised, two-way (genesagainst samples), hierarchical cluster analysis (HCA). Remarkably,
three PPD-treated cell samples (24p20, 48p20, 48p25) clearly
grouped into one cluster, while three normal control cell samples
also grouped together and formed a cluster (Fig. 5A). 204 genes
signiﬁcantly changed (over 1.5-fold) after PPD treatment. A sub-
analysis based 79 genes signiﬁcantly altered (over 2-fold)
(Fig. 5B). 20 of the most upregulated and downregulated genes
were compiled based on the microarray data, shown in Tables 1
and 2.
Among the genes that were signiﬁcantly altered when treated
with PPD in HCT-116 cells, six downregulated genes (CLSPN,
CCNA2, SPAG5, DNM3, DHCR24, DSCC1) and ﬁve upregulated genes
(BTG1, DDIT4, PDCD4, KLF4, NRP1) were validated by quantitative
real-time RT-PCR. The same RNA samples for microarray were used
to generate cDNA templates for reverse transcription reactions. The
SYBR green-based real-time RT-PCR analysis was then carried out.
Consistent with the microarray data, the 11 selected genes showed
the same expression proﬁle as the microarray data presented
(Fig. 5C and D).
3.6. Pathway analysis microarray data of HCT-116 cells treated with
PPD
We performed gene network analysis using the 204 signiﬁcant
genes from our microarray analysis through the Ingenuity Pathway
Fig. 4. (A) Bar plot of PPD-induced apoptosis in HCT-116 and SW-480 cells at 48 h. Data are presented as a percentage of total cells counted, three independent assays calculated.
** P < 0.01, compared with control. (B) Bar plot of PPD-induced G1 cell redistribution in HCT-116 and SW-480 cells at 48 h. Three independent assays are calculated * P < 0.05,
compared with control.
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tumorigenesis is shown in Fig. 6A. Among them, apoptosis, prolif-
eration, and angiogenesis were signiﬁcantly induced. This is
consistent with our in vitro data, suggesting that PPD is probably
involved in cancer cell growth by modulating these processes. The
selected regulatory cell death pathway gene network is shown in
Fig. 6B, in which 23 affected genes of this network were either
upregulated or downregulated after PPD treatment. Among the
genes, DR4 and DR5 are important members of the tumor necrosis
factors (TNF) family. It appears that HCT-116 cell apoptosis was
induced after PPD exposure by the interaction of p53 and DR4/DR5,
and suggests that the TRAIL pathway was associated with the PPD
activities.
4. Discussion
CRC is one of the most common cancers worldwide (18).
Although the CRC tumorigenesis process offers a good under-
standing of human solid malignancies, the medical management of
advanced colon cases remains highly challenging. Our previous
in vitro studies observed that American ginseng exhibited anti-
cancer potential in human colorectal cancer cells (19,20).
PPD, one of the aglycones of American ginseng, has been shown
to have cytotoxic activities against different cancer cells such as THP-
1 leukemia cells and Caco-2 colorectal cancer cells (21,22). Recently,
PPD and its analogs have also been reported for their signiﬁcant
cancer cell growth inhibitory effects on human lung adenocarcinoma
and oral squamous cell carcinoma. However, previous PPD studies
focused on in vitro evaluations (23,24). This study conﬁrmed the
anti-CRC effects of PPD in a dose-related manner using an in vivo
xenograft nude mice model. Using a panel of colorectal cell lines, we
observed that PPD suppressed cell proliferation, arrested speciﬁc cell
cycle distribution, and promoted apoptosis. This is consistent with a
previous observation that PPD and other ginsenoside aglycones are
strong promoters of apoptosis (25). Recent pre-clinical research re-
ported that orally administered PPD exhibited therapeutic activity on
a home-sensitive prostate cancer model (26), addressing that the
activity beneﬁted from in situ apoptosis and proliferation inhibition.
Interestingly, our study observed that PPD inhibited HCT-116 cell
proliferation signiﬁcantlymore than the other two colon cancer cells.
Based on the p53 status in these cell lines, it is suggested that p53
might contribute to the difference.
Previous in vitro studies that involved a PPD metabolized
product (compound K or CK) revealed that it had an anticancereffect in human CRC cell lines. CK could induce apoptosis by acti-
vation of CAMK-IV/AMPK pathways in HT-29 cells (27). Another
report also showed that PPD could suppress the activation of NF-kB
pathway and MMP-9 expression, which would inhibit murine CRC
cell migration and invasion. However, activity pathway of PPD as an
anticancer agent in human CRC is largely unknown.
In a previous study, we reported gene proﬁle and pathway
activation after ginsenoside Rg3 treatment. In this study, we
observed that the ephrin receptor (Ephs) pathway is the most
affected. Ephs are the largest receptors in the tyrosine kinase family
of transmembrane proteins, capable of recognizing signals from the
cell environment and inﬂuencing cell-cell interaction and cell
migration (28). To explore the molecular mechanism of the anti-
cancer properties of PPD, we performed a screening test to distin-
guish the potential targets of PPD using a genome-wide microarray
analysis. Hundreds of genes were transcriptionally activated or
downregulated after PPD treatment in HCT-116 cells. Among them,
attention was paid to the core pathways mainly related cancer and
some crucial oncogenes and tumor suppressors. It is conceivable
that the potential molecular targets might be those candidate genes
that we reported.
Top 20 upregulated and downregulated genes are shown in
Tables 1 and 2. BTG1, a cell proliferative inhibitory factor, was
upregulated, which was conﬁrmed by qPCR analysis (29). DDIT4,
the DNA-damage-inducible transcript 4, was reported as m-TOR
inhibitor. Overexpression of DDIT4 promotes apoptosis in different
types of cancer cells (30). Upregulation of BTG1 and DDIT4 could
contribute to PPD's effect on the cell proliferation and apoptosis in
the human CRC.
CCNA2, a key regulator of the regular cell cycle progression, is
overexpressed in multiple cancer malignancies such as lung, liver,
colon, and breast cancers (31e33). Any treatment suppressing
CCNA2 expression would be beneﬁcial in inhibiting tumor growth.
In our study, CCNA2 was decreased in HCT-116 cells when treated
with PPD in both microarray screening and real-time PCR arrays.
CCNE2 (cyclin E2), a signiﬁcant overexpression gene in tumor-
derived cells, was downregulated by PPD. Cyclin E2 is reported to
speciﬁcally interact with CIP/KIP family of CDK inhibitors, and plays
a role in cell cycle G1/S transition. The expression of cyclin E2 peaks
at the G1-S phase and exhibits a pattern of tissue speciﬁcity distinct
from that of cyclin E1 (34,35). In addition, although not involved in
top 20 upregulated gene list, CDKN1A (p21) was signiﬁcantly
upregulated by the treatment of PPD, which is consistent with
previous reports that PPD analogs increased p21 expression in
Fig. 5. mRNA expression proﬁling and quantitative real-time PCR (qPCR) analysis after PPD treatment in HCT-116 cells. (A) Comparison of gene expression proﬁles of control HCT-116 cells and PPD-treated cells. The heat map was
generated using the expression ratios of 4187 genes that differed in PPD-treated HCT-116 cells compared to no-treated cells, according to signiﬁcance analysis of microarrays (SAM). Red represents overexpressed mRNAs. Green
represents underexpressed mRNAs, compared to the counterparts. 204 genes signiﬁcantly changed (above 1.5-fold) after PPD treatment. (B) Sub-analysis of signiﬁcant 79 genes transcriptionally deregulated (threshold above 2-fold)
when treated with PPD. (C) Six selected down regulated genes screening out of the microarray analysis are veriﬁed by qPCR. (D) Five selected upregulated genes screening out of the microarray analysis are conﬁrmed by qPCR array.
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Table 1
Top 20 upregulated genes induced by PPD in HCT-116 cells.
Gene Symbol Gene assignment 48NC1 48NC2 48NC3 24P20 48P20 48P25 Fold change (Unlogged)
SLC7A11 NM_014331 1.099 1.147 1.028 0.993 1.463 1.547 5.445
CHAC1 NM_024111 0.923 1.322 0.798 0.566 1.424 1.728 4.977
DDIT4 NM_019058 0.952 0.941 0.987 1.298 1.287 1.081 4.546
C12orf39 NM_030572 0.715 1.203 0.948 0.645 1.296 1.558 4.459
TCP11L2 NM_152772 0.820 0.807 0.601 0.264 1.404 2.022 4.195
NRP1 NM_003873 0.818 1.055 0.761 0.952 1.149 1.198 3.934
ASNS NM_133436 0.816 0.829 0.829 1.066 1.130 1.211 3.894
CSTA NM_005213 0.859 0.729 0.836 1.132 1.057 1.033 3.684
SERPINE1 NM_000602 0.908 0.834 0.715 0.589 0.891 1.538 3.677
SESN2 NM_031459 0.662 0.843 0.642 0.370 1.137 1.574 3.534
ABCC3 NM_003786 0.727 0.747 0.855 0.721 0.867 1.382 3.467
SLFN5 NM_144975 0.703 0.666 0.802 0.137 1.180 1.496 3.402
SLC6A9 NM_201649 0.668 0.699 0.832 0.629 0.942 1.263 3.247
PCK2 NM_004563 0.564 0.915 0.673 0.624 1.203 1.043 3.219
OR2A20P NR_002158 0.673 0.637 0.774 0.750 0.930 1.201 3.173
UPP1 NM_003364 0.648 0.629 0.826 0.681 0.768 1.144 2.983
BTG1 NM_001731 0.706 0.647 0.689 0.719 0.712 1.179 2.965
C9orf150 NM_203403 0.701 0.730 0.557 0.351 0.936 1.268 2.949
STC2 NM_003714 0.584 0.706 0.737 0.444 0.951 1.156 2.937
FAM129A NM_052966 0.818 0.731 0.422 0.286 0.983 1.237 2.898
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plexes, in preventing the G1-S transition, leading to G1 arrest and
inhibiting cell proliferation (38). Our cell cycle and gene expression
assays suggested that the PPD-induced G1 cell cycle checkpoint
blockage might result from the regulation of a number of gene
clusters such as CDKN1A, CCNE2 and CCNA2.
An important issue was pathway activation or suppression. In
our gene expression analysis, apoptosis regulation, NF-kB, and m-
TOR pathways, were transcriptionally activated when treated with
PPD. A number of studies have investigated that these pathways are
the crucial and essential in tumor initiation and progression
(39e41). Among these pathways, the p53 pathwaymight be pivotal
to controlling the human cancer cell response to PPD exposure. Two
important members of the TNF family, DR4 and DR5, were signiﬁ-
cantly upregulated in our assays.
Previous studies have shown that the upregulation of DR4 and
DR5 sensitized to tumor necrosis factor-related apoptosis-inducing
ligand or TRAIL-induced apoptosis (42,43). The relationship be-
tween the TRAIL and human malignancies has been shown (44,45).
Since TRAIL-mediated suppression of inﬂammation correlates with
suppression of tumor development, it has been used as a target ofTable 2
Top 20 downregulated genes induced by PPD in HCT-116 cells.
Gene Symbol Gene assignment 48NC1 48NC2 48NC3
HIST1H2BM NM_003521 0.783 0.713 1.161
DHRS2 NM_182908 0.692 0.777 0.788
ACAT2 NM_005891 0.623 0.711 0.693
HIST1H3J NM_003535 0.887 0.609 0.632
INSIG1 NM_005542 0.539 0.551 0.581
ADAM21 NM_003813 0.458 0.476 0.778
SYTL2 NM_206927 0.457 0.566 0.596
ADAM21 NM_003813 0.435 0.318 0.732
CENPI NM_006733 0.430 0.496 0.552
CCNE2 NM_057749 0.525 0.493 0.378
SHCBP1 NM_024745 0.443 0.496 0.517
HMGCS1 NM_001098272 0.531 0.526 0.266
KIF11 NM_004523 0.511 0.440 0.502
HIST1H2AB NM_003513 0.430 0.555 0.406
STARD4 NM_139164 0.444 0.386 0.544
HIST1H2BF NM_003522 0.502 0.389 0.503
FAM83D NM_030919 0.480 0.464 0.505
DLGAP5 NM_014750 0.470 0.558 0.530
PLA2G4A NM_024420 0.347 0.444 0.568
CLSPN NM_022111 0.394 0.437 0.486several anticancer therapeutics (46). In particular, the expression of
TRAIL receptors DR4 and DR5 are often altered in patients with
colon cancer. Activation of DR4 and DR5 selectively induces
apoptosis in colon cancer cells (47).
Ginseng is one of the most commonly used botanical in the
world. After oral administration, parent ginseng compounds were
biotransformed to Rg3 and PPD in the gut before absorption.
Recently, it was observed that the p53-DR5 crosstalk regulatory
network might contribute to the induced apoptosis by ginsenoside
Rg3 in hepatoma cells (48). Consistent with these studies, our data
suggested that PPD-induced colon cancer cell apoptosis is partially
mediated by the regulation of crosstalk of the p53-DR4/DR5
interaction, a TRAIL pathway. PPDmay have potential in preventing
colorectal tumorigenesis and treating CRC alone or in combination
with other chemotherapeutic agents (26).
In summary, the present study demonstrated that PPD
possessed signiﬁcant antitumor effects in an in vivomodel. Human
colorectal cancer lines, especially HTC-116 cells, are highly sensitive
to the growth inhibition by PPD. The effects of the compound are
associated with G1 cell cycle arrest and induction of apoptosis.
Microarray analysis showed that PPD inhibited CRC cell growth by24P20 48P20 48P25 Fold change (Unlogged)
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Fig. 6. Pathway analysis of microarray data from HCT-116 cancer cells treated with PPD. (A) 10 selected tumorigenesis-related pathways are shown. (B) Cell death regulatory genes
network plot. 23 affected assorted by microarray analysis are presented, marked with small circle.
Z. Zhang et al. / Journal of Pharmacological Sciences 127 (2015) 83e9190activation of a cluster of gene expression, including oncogenes as
well as tumor suppressors. Our data suggested that by regulating
the interactions between p53 and DR4/DR5, the TRAIL pathway
played an important role in PPD’s CRC inhibition. The logical next
step for TRAIL apoptotic pathway veriﬁcation should be employing
western blot or immunostaining to evaluate expressions of the key
target regulators. These observations should lead to the marker
identiﬁcations that reﬂect the responsiveness of colon tumor to
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